Development

AMPLITUDE, INC. (NASDAQ: AMPL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amplitude, Inc.

Retrieved on: 
Monday, March 25, 2024
Growth, Acceleration, District court, COVID-19, Defendant, News, Complaint, Action Replay, Court, Advertising, Development, Security (finance)

If you purchased or acquired Amplitude common stock, and/or would like to discuss your legal rights and options please visit Amplitude, Inc.

Key Points: 
  • If you purchased or acquired Amplitude common stock, and/or would like to discuss your legal rights and options please visit Amplitude, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Retrieved on: 
Monday, March 25, 2024
Disease, Development, Immunotherapy, Partnership, T1D, Patient, NMRC, Research, Mortality, Death, Breakthrough therapy, Infection, CDC, Vaccination, Safety, SAB, Therapy, Vaccine, Immunoglobulin G, Food

The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr.

Key Points: 
  • The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr.
  • SAB has utilized its proprietary DiversitAb™ platform to manufacture SAB-176, fully human polyclonal antibodies targeting influenza from Transchromosomic (Tc) Bovine™.
  • SAB-176 is a novel multi-target biologic that has shown sustained neutralization activity across multiple virus strains of Influenza A and B.
  • Influenza is responsible for approximately 226,000 excess hospitalizations and 30,000 to 50,000 deaths each year in the United States alone.

Dreaming Out Loud Hosts Annual Spring Festival to Celebrate Community and Healthy Food

Retrieved on: 
Monday, March 25, 2024
Farm, Friends, Spring Festival, Kelly Miller, Dreaming Out Loud, The Spring Festival, Development, Food, Communications manager, Entertainment

Washington, DC, March 25, 2024 (GLOBE NEWSWIRE) -- Dreaming Out Loud is excited to announce our highly anticipated annual Spring Festival, scheduled for April 27th from 10am to 2pm.

Key Points: 
  • Washington, DC, March 25, 2024 (GLOBE NEWSWIRE) -- Dreaming Out Loud is excited to announce our highly anticipated annual Spring Festival, scheduled for April 27th from 10am to 2pm.
  • This event promises a day filled with food, drinks, and a plethora of engaging activities designed to unite and empower our community.
  • "At Dreaming Out Loud, we are dedicated to fostering equitable food systems that strengthen marginalized communities," said Sherita Brace, Development Director at Dreaming Out Loud.
  • Whether you're a food enthusiast, a supporter of our community initiatives, or simply looking for a day of fun, the Spring Festival promises something for everyone.

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

Retrieved on: 
Monday, March 25, 2024
Retina, Research, Gene, Development, IRD, Leber congenital amaurosis, Retinitis pigmentosa, Paratriathlon, Patient, Bayer, Foundation Fighting Blindness, Visual impairment, University, Wilfrid Sellars, Senior, IND, Therapy, IPSC, Usher syndrome, B cell, Pharmaceutical industry

The new cohort will include patients living with IRDs caused by mutations in multiple genes.

Key Points: 
  • The new cohort will include patients living with IRDs caused by mutations in multiple genes.
  • “BlueRock is developing a pipeline of cell therapies that we believe has great potential for restoring vision in people living with blindness caused by retinal disease,” said Ahmed Enayetallah, Senior Vice President and Head of Development for BlueRock Therapeutics.
  • Primary photoreceptor diseases are a subgroup of inherited retinal diseases that includes retinitis pigmentosa and cone- rod dystrophies.
  • OpCT-001 aims to restore vision loss caused by these diseases by replacing degenerated tissue in the retina with functional cells.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Amplitude, Inc. - AMPL

Retrieved on: 
Saturday, March 23, 2024
Prior, News, Ext, LLP, Complaint, Amplitude, Pomerantz, Action Replay, Court, Development

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amplitude, Inc. (“Amplitude” or the “Company”) (NASDAQ: AMPL).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amplitude, Inc. (“Amplitude” or the “Company”) (NASDAQ: AMPL).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether Amplitude and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Sunlands Technology Group Announces Unaudited Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 22, 2024
Financial management, PIN, Growth, Information technology, Mentorship, H.10, RMB, Capital expenditure, STG, Student, Translation, Investment, Share repurchase, Marketing, Development, Video game

BEIJING, March 22, 2024 (GLOBE NEWSWIRE) -- Sunlands Technology Group (NYSE: STG) (“Sunlands” or the “Company”), a leader in China’s online post-secondary and professional education, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • BEIJING, March 22, 2024 (GLOBE NEWSWIRE) -- Sunlands Technology Group (NYSE: STG) (“Sunlands” or the “Company”), a leader in China’s online post-secondary and professional education, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023.
  • Net income margin1 was 28.6% in the fourth quarter of 2023, compared to 31.3% in the fourth quarter of 2022.
  • Net income for the fourth quarter of 2023 was RMB155.2 million (US$21.9 million), as compared to RMB181.0 million in the fourth quarter of 2022.
  • Capital expenditures were RMB0.2 million (US$0.1 million) in the fourth quarter of 2023, as compared to RMB0.7 million in the fourth quarter of 2022.

FuelPositive Files Patent for Green Aqueous Ammonia Production Module and Provides Update on First Farm-Ready System

Retrieved on: 
Friday, March 22, 2024
Well, Research, Development, Farmer, Heat, Nitrogen, Chairperson, Ammonia, Transport, Running, EEStor, Chemical substance, NH3, Engineering, Fertilizer, Safety, Chemical engineering, FAT, Acceptance, Manitoba Hydro

WATERLOO, Ontario, March 21, 2024 (GLOBE NEWSWIRE) -- FuelPositive Corporation, a leading Green Ammonia Company (TSX.V: NHHH) (OTCQB: NHHHF) (the “Company” or “FuelPositive”) is pleased to announce that it has filed a provisional patent for its new Green Aqueous Ammonia add-on module systems: the FP300A and FP1500A.

Key Points: 
  • This groundbreaking integrated module provides farmers with a method for producing aqueous ammonia of adjustable nitrogen concentration from their FuelPositive on-farm system.
  • The FP300 or FP1500 can now be upgraded to FP300A or FP1500A systems, thereby transforming Green Anhydrous Ammonia into Green Aqueous Ammonia Fertilizer.
  • Green Aqueous Ammonia requires fewer storage and handling safeguards than Green Anhydrous Ammonia, making it more accessible to a broader range of agricultural applications.
  • In response to farmers' diverse needs, we've expanded our containerized Green Anhydrous Ammonia system to include a Green Aqueous Ammonia module.

BTCS Reports 2023 Results

Retrieved on: 
Friday, March 22, 2024
Crypto, BTCS, Algorithm, Growth, Blockchain, Research, ASU, Acquisition, Spring, Bank statement, ETH, BTC, Ecosystem, Optimism, ETF, Development, Cryptocurrency

Silver Spring, MD, March 22, 2024 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, announced its results for the fiscal year ended December 31, 2023 (“2023”).

Key Points: 
  • Silver Spring, MD, March 22, 2024 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, announced its results for the fiscal year ended December 31, 2023 (“2023”).
  • Revenue for the fourth quarter of 2023 increased 20% year-over-year, benefiting from a surge in crypto market prices in December 2023.
  • 2023 Cash & Crypto Value: $26.7 million as of December 31, 2023, marking a 82% year-over-year increase.
  • In 2023, our strategic initiatives delivered strong results, culminating in significant momentum as we moved into 2024.

AMPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amplitude, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Friday, March 22, 2024
Growth, Acceleration, COVID-19, News, IPO, Complaint, Development, Court, Person, Cryptocurrency

Amplitude is a technology company that helps businesses analyze data for their digital products and track customer interactions.

Key Points: 
  • Amplitude is a technology company that helps businesses analyze data for their digital products and track customer interactions.
  • Beginning in September 2021, Amplitude claimed to be experiencing extraordinary growth due to “strong demand for [its products]” and a “robust” expansion from existing customers.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.